DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

36.37 30.87 26.17 26.00
P/S ratio
5.83 5.56 5.02 5.18
P/FCF ratio
24.78 24.04 16.92 18.32
P/Operating CF
39.88 88.09 46.01 95.62
P/B ratio
9.65 9.43 8.18 9.82
EV/Sales
5.54 5.56 4.94 5.19
EV/EBITDA
24.47 22.27 18.40 18.39
EV/FCF
23.55 24.06 16.64 18.37
Current Ratio
1.56 1.88 1.95 1.73
Net Debt/EBITDA
(6.80) (1.95) (3.64) (1.82)
Debt/Equity
0.45 0.45 0.42 0.47
Earnings Yield
2.75% 3.24% 3.82% 3.85%
Free Cash Flow Yield
4.04% 4.16% 5.91% 5.46%
Free Cash Flow per Share
1.48 0.49 1.17 0.48
Book value per Share
6.97 7.04 7.68 6.86
Free Cash Flow
579.40 192.10 449.00 184.50
EV/EBIT
32.16 28.42 23.01 22.66
Other line items

Show all line items

Columns are period end dates